BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 24512308)

  • 21. Human endometrial cytodifferentiation by histone deacetylase inhibitors.
    Uchida H; Maruyama T; Nagashima T; Ono M; Masuda H; Arase T; Sugiura I; Onouchi M; Kajitani T; Asada H; Yoshimura Y
    Hum Cell; 2006 Feb; 19(1):38-42. PubMed ID: 16643606
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differential effects of class I isoform histone deacetylase depletion and enzymatic inhibition by belinostat or valproic acid in HeLa cells.
    Dejligbjerg M; Grauslund M; Litman T; Collins L; Qian X; Jeffers M; Lichenstein H; Jensen PB; Sehested M
    Mol Cancer; 2008 Sep; 7():70. PubMed ID: 18789133
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Histone deacetylase inhibitor induction of epithelial-mesenchymal transitions via up-regulation of Snail facilitates cancer progression.
    Jiang GM; Wang HS; Zhang F; Zhang KS; Liu ZC; Fang R; Wang H; Cai SH; Du J
    Biochim Biophys Acta; 2013 Mar; 1833(3):663-71. PubMed ID: 23246564
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine.
    Ahrens TD; Timme S; Hoeppner J; Ostendorp J; Hembach S; Follo M; Hopt UT; Werner M; Busch H; Boerries M; Lassmann S
    Epigenetics; 2015; 10(5):431-45. PubMed ID: 25923331
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Histone deacetylase inhibitor pre-treatment enhances the efficacy of DNA-interacting chemotherapeutic drugs in gastric cancer.
    Amnekar RV; Khan SA; Rashid M; Khade B; Thorat R; Gera P; Shrikhande SV; Smoot DT; Ashktorab H; Gupta S
    World J Gastroenterol; 2020 Feb; 26(6):598-613. PubMed ID: 32103870
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma.
    Bensaid D; Blondy T; Deshayes S; Dehame V; Bertrand P; Grégoire M; Errami M; Blanquart C
    Clin Epigenetics; 2018; 10():79. PubMed ID: 29946373
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Trichostatin A augments esophageal squamous cell carcinoma cells migration by inducing acetylation of RelA at K310 leading epithelia-mesenchymal transition.
    Huang K; Liu Y; Gu C; Liu D; Zhao B
    Anticancer Drugs; 2020 Jul; 31(6):567-574. PubMed ID: 32282366
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Overcoming inherent resistance to histone deacetylase inhibitors in multiple myeloma cells by targeting pathways integral to the actin cytoskeleton.
    Mithraprabhu S; Khong T; Spencer A
    Cell Death Dis; 2014 Mar; 5(3):e1134. PubMed ID: 24651437
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Experience Modulates the Effects of Histone Deacetylase Inhibitors on Gene and Protein Expression in the Hippocampus: Impaired Plasticity in Aging.
    Sewal AS; Patzke H; Perez EJ; Park P; Lehrmann E; Zhang Y; Becker KG; Fletcher BR; Long JM; Rapp PR
    J Neurosci; 2015 Aug; 35(33):11729-42. PubMed ID: 26290249
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of natural and synthetic histone deacetylase inhibitors on chromatin.
    Licciardi PV; Kwa FA; Ververis K; Di Costanzo N; Balcerczyk A; Tang ML; El-Osta A; Karagiannis TC
    Antioxid Redox Signal; 2012 Jul; 17(2):340-54. PubMed ID: 22229817
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of Histone Deacetylase Inhibitors on microRNA Expression and Cancer Therapy: A Review.
    Ali SR; Humphreys KJ; McKinnon RA; Michael MZ
    Drug Dev Res; 2015 Sep; 76(6):296-317. PubMed ID: 26303212
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design, synthesis, and characterization of α, β-unsaturated carboxylic acid, and its urea based derivatives that explores novel epigenetic modulators in human non-small cell lung cancer A549 cell line.
    Chidambaram A; Sundararaju K; Chidambaram RK; Subbiah R; Jayaraj JM; Muthusamy K; Vilwanathan R
    J Cell Physiol; 2018 Jul; 233(7):5293-5309. PubMed ID: 29215703
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Resveratrol sensitizes acute myelogenous leukemia cells to histone deacetylase inhibitors through reactive oxygen species-mediated activation of the extrinsic apoptotic pathway.
    Yaseen A; Chen S; Hock S; Rosato R; Dent P; Dai Y; Grant S
    Mol Pharmacol; 2012 Dec; 82(6):1030-41. PubMed ID: 22923501
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Over-expression of clusterin is a resistance factor to the anti-cancer effect of histone deacetylase inhibitors.
    Liu T; Liu PY; Tee AE; Haber M; Norris MD; Gleave ME; Marshall GM
    Eur J Cancer; 2009 Jul; 45(10):1846-54. PubMed ID: 19342222
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HDAC inhibitors induce transcriptional repression of high copy number genes in breast cancer through elongation blockade.
    Kim YJ; Greer CB; Cecchini KR; Harris LN; Tuck DP; Kim TH
    Oncogene; 2013 Jun; 32(23):2828-35. PubMed ID: 23435418
    [TBL] [Abstract][Full Text] [Related]  

  • 36. RNH1 regulation of reactive oxygen species contributes to histone deacetylase inhibitor resistance in gastric cancer cells.
    Zhu Y; Das K; Wu J; Lee MH; Tan P
    Oncogene; 2014 Mar; 33(12):1527-37. PubMed ID: 23584480
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular and biologic analysis of histone deacetylase inhibitors with diverse specificities.
    Newbold A; Matthews GM; Bots M; Cluse LA; Clarke CJ; Banks KM; Cullinane C; Bolden JE; Christiansen AJ; Dickins RA; Miccolo C; Chiocca S; Kral AM; Ozerova ND; Miller TA; Methot JL; Richon VM; Secrist JP; Minucci S; Johnstone RW
    Mol Cancer Ther; 2013 Dec; 12(12):2709-21. PubMed ID: 24092806
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel histone deacetylase inhibitor, CG0006, induces cell death through both extrinsic and intrinsic apoptotic pathways.
    Hwang JJ; Kim YS; Kim MJ; Jang S; Lee JH; Choi J; Ro S; Hyun YL; Lee JS; Kim CS
    Anticancer Drugs; 2009 Oct; 20(9):815-21. PubMed ID: 19644355
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Proteomics analysis of histone deacetylase inhibitor-resistant solid tumors reveals resistant signatures and potential drug combinations.
    Hao BB; Ma K; Xu JY; Fan RF; Zhao WS; Jia XL; Zhai LH; Lee S; Xie D; Tan MJ
    Acta Pharmacol Sin; 2024 Jun; 45(6):1305-1315. PubMed ID: 38383757
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Histone deacetylase regulation of immune gene expression in tumor cells.
    Khan AN; Tomasi TB
    Immunol Res; 2008; 40(2):164-78. PubMed ID: 18213528
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.